In the BioHarmony Drug Report Database

"Preview" Icon

Sotagliflozin

Zynquista (sotagliflozin) is a small molecule pharmaceutical. Sotagliflozin was first approved as Zynquista on 2019-04-26. It has been approved in Europe to treat type 1 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1.

 

Trade Name

 

Zynquista
 

Common Name

 

sotagliflozin
 

ChEMBL ID

 

CHEMBL3039507
 

Indication

 

type 1 diabetes mellitus
 

Drug Class

 

Phlorozin derivatives, phenolic glycosides

Image (chem structure or protein)

Sotagliflozin structure rendering